+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07714668

Phase II Study of SYS6041 Combination Therapy Evaluating Safety and Efficacy in Recurrent Ovarian Cancer

Led by CSPC Megalith Biopharmaceutical Co.,Ltd. · Updated on 2026-08-31

171

Participants Needed

1

Research Sites

69 weeks

Total Duration

AI-Summary

What This Trial Is About

This clinical trial is an open-label, multicenter Phase II study investigating SYS6041 combination therapy in subjects with recurrent ovarian cancer. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary effectiveness of SYS6041 when combined with other agents. Participants include those with high-grade serous ovarian, epithelial fallopian tube carcinoma, or primary peritoneal cancer who have experienced disease progression or intolerance to recent treatments. Participants will receive SYS6041 combined with various agents such as carboplatin, paclitaxel, bevacizumab, or enlonstobart. Each treatment cycle lasts three weeks, and participants continue until disease progression, intolerable side effects, starting new anti-tumor therapy, withdrawal, loss to follow-up, or death. Different treatment groups receive distinct combinations, with dosing schedules every three weeks through intravenous administration. During the study, participants will undergo assessments including monitoring of dose-limiting toxicities, adverse events, pharmacokinetic measures, and tumor response evaluations. Follow-up for outcomes like progression-free survival and overall survival may last up to approximately three years. Safety and response data will be collected throughout treatment and up to 30 days after the last dose, with some measures tracked for several years to evaluate long-term effects.

CONDITIONS

Brief Title

A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

Research Team

C

Clinical Trials Information Group officer

X

Xiaohua Wu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here